RecruitingPhase 1

A Phase I Clinical Trial to Assess the Safety and Immunogenicity of DX-104

Australia30 participantsStarted 2026-03-20

Plain-language summary

A randomized, double-blinded, positive-controlled clinical trial will be conducted to observe the safety and immunogenicity of DX-104 in adults 18 to 50 years of age.

Who can participate

Age range18 Years – 50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Healthy male or female participants aged 18 to 50 years (inclusive) at the time of screening, who can provide valid legal identification.
✓. Willing and able to give written informed consent before any study-related activities are carried out and must be able to understand the full nature and purpose of the trial, including possible risks and adverse effects.
✓. Willing and able to comply with all study procedures and available for the entire duration of the study follow-up.
✓. Participants must have a Body Mass Index (BMI) between ≥18.0 and ≤32.0 kg/m2 at screening.
✓. For female participants at least 1 of the following conditions must apply:
✓. Females should not be currently breastfeeding, and should not breastfeed for the duration of the study.
✓. Male participants are able to participate if they:

What they're measuring

To assess the overall safety of DX-104

Timeframe: Through study completion, an average of 1 year.

Trial details

NCT IDNCT07395739

SponsorShanghai Yuguan Biotech Co., Ltd.（Delonix Bioworks)

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2027-05-01

Contact for this trial

Project Manager

（+86）021-50360201 clic@delonixbio.com

View on ClinicalTrials.gov More Neisseria Meningitidis Serogroup B trials